Asian Value Stocks That May Be Trading Below Their Worth In September 2026
As Asian markets continue to navigate a landscape marked by technological advancements and shifting economic conditions, investors are increasingly on the lookout for stocks that may be trading below their intrinsic value. In such an environment, identifying undervalued stocks requires a keen understanding of market trends and careful analysis of company fundamentals, which can reveal opportunities for potential growth amidst broader market fluctuations.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Yadea Group Holdings (SEHK:1585) | HK$9.085 | HK$17.84 | 49.1% |
| Visional (TSE:4194) | ¥8950.00 | ¥17814.04 | 49.8% |
| SIMMTECH (KOSDAQ:A222800) | ₩123400.00 | ₩246461.63 | 49.9% |
| Natural Food International Holding (SEHK:1837) | HK$1.45 | HK$2.89 | 49.8% |
| Link and Motivation (TSE:2170) | ¥661.00 | ¥1311.09 | 49.6% |
| Karmarts (SET:KAMART) | THB6.75 | THB13.40 | 49.6% |
| Geo Energy Resources (SGX:RE4) | SGD0.565 | SGD1.13 | 49.8% |
| Delton Technology (Guangzhou) (SZSE:001389) | CN¥155.32 | CN¥307.10 | 49.4% |
| China Tobacco International (HK) (SEHK:6055) | HK$24.54 | HK$48.37 | 49.3% |
| BuySell TechnologiesLtd (TSE:7685) | ¥3000.00 | ¥5912.96 | 49.3% |
Let's dive into some prime choices out of the screener.
L&C BIOLTD (KOSDAQ:A290650)
Overview: L&C BIO Co., LTD is a research and development company focused on tissue regeneration medicine, with a market cap of ₩1.46 billion.
Operations: The company generates revenue from its Medical Products segment, amounting to ₩98.10 billion.
Estimated Discount To Fair Value: 14.0%
L&C BIO Co., LTD is trading 14% below its fair value estimate of ₩54,000, with analysts agreeing on a potential price rise of 75.9%. Despite recent volatility and a follow-on equity offering worth ₩140.6 billion, the company shows strong growth prospects with forecasted earnings growth of 148.51% annually and revenue expected to grow at 40% per year, significantly outpacing the market average in Korea.
- The analysis detailed in our L&C BIOLTD growth report hints at robust future financial performance.
- Click to explore a detailed breakdown of our findings in L&C BIOLTD's balance sheet health report.
Geo Energy Resources (SGX:RE4)
Overview: Geo Energy Resources Limited is an investment holding company involved in the mining, production, and trading of coal with a market capitalization of SGD1 billion.
Operations: Geo Energy Resources Limited generates revenue primarily from its coal mining segment, amounting to $465.50 million.
Estimated Discount To Fair Value: 49.8%
Geo Energy Resources is trading at a significant discount to its estimated cash flow value of S$1.13, with current trading around S$0.57. Despite recent shareholder dilution, the company anticipates substantial earnings growth of 48.39% annually and revenue growth of 24.3%, outpacing the Singapore market averages. The operational launch of MBJ Integrated Infrastructure is expected to boost EBITDA by up to US$600 million annually, enhancing coal production efficiency and creating new revenue streams through third-party logistics services.
- Our earnings growth report unveils the potential for significant increases in Geo Energy Resources' future results.
- Navigate through the intricacies of Geo Energy Resources with our comprehensive financial health report here.
Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016)
Overview: Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. operates in the biotechnology sector and has a market cap of CN¥8.92 billion.
Operations: Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. generates revenue through its biotechnology operations, contributing significantly to its CN¥8.92 billion market capitalization.
Estimated Discount To Fair Value: 30.2%
Shandong Bailong Chuangyuan Bio-Tech is trading at CNY 21.24, significantly below its estimated future cash flow value of CNY 30.45, suggesting undervaluation. Recent earnings show strong growth with sales reaching CNY 759.46 million and net income at CNY 210.64 million for the first half of 2026. Despite high non-cash earnings and a low dividend coverage by free cash flows, the company forecasts robust revenue growth at 19.6% annually, outpacing China's market average.
- Insights from our recent growth report point to a promising forecast for Shandong Bailong Chuangyuan Bio-Tech's business outlook.
- Take a closer look at Shandong Bailong Chuangyuan Bio-Tech's balance sheet health here in our report.
Seize The Opportunity
- Unlock more gems! Our Undervalued Asian Stocks Based On Cash Flows screener has unearthed 213 more companies for you to explore.Click here to unveil our expertly curated list of 216 Undervalued Asian Stocks Based On Cash Flows.
- Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com